Pyrimidines

"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.

Descriptor ID	D011743
MeSH Number(s)	D03.383.742
Concept/Terms	Pyrimidines Pyrimidines

Below are MeSH descriptors whose meaning is more general than "Pyrimidines".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrimidines [D03.383.742]

Below are MeSH descriptors whose meaning is related to "Pyrimidines".

Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.

Bar chart showing 84 publications over 24 distinct years, with a maximum of 9 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1998	1	1	2
2001	0	1	1
2002	1	0	1
2003	0	2	2
2004	1	2	3
2005	0	2	2
2006	3	1	4
2007	3	0	3
2008	1	4	5
2009	3	1	4
2010	4	1	5
2011	3	6	9
2012	2	3	5
2013	3	3	6
2014	2	4	6
2015	2	1	3
2016	0	3	3
2017	5	3	8
2018	1	1	2
2019	2	0	2
2020	1	2	3
2021	0	3	3
2023	1	0	1

Below are the most recent publications written about "Pyrimidines" by people in Profiles.

Sutar Y, Singh SK, Dhoble S, Mali J, Adams J, Yadavalli T, Date AA, Shukla D. Oral Self-Nanoemulsifying System Containing Ionic Liquid of BX795 Is Effective against Genital HSV-2 Infection in Mice. ACS Infect Dis. 2024 Jan 12; 10(1):93-106.

View in: PubMed
Rudra S, Shaul E, Conrad M, Patel T, Moore A, Dawany N, Canavan MC, Sullivan KE, Behrens E, Kelsen JR. Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 06; 20(6):1408-1410.e2.

View in: PubMed
Borrero-Garc?a LD, Del Mar Maldonado M, Medina-Vel?zquez J, Troche-Torres AL, Velazquez L, Grafals-Ruiz N, Dharmawardhane S. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. BMC Cancer. 2021 Jun 01; 21(1):652.

View in: PubMed
Triebwasser MP, Barrett DM, Bassiri H, Bunin N, Elgarten C, Freedman J, Geera AS, Monos D, Lambert MP, Olson T, Seif AE, Paessler M, Petrosa W, Reilly AF, Romberg N, Sullivan KE, Quinn GZ, Behrens E, Teachey DT. Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Pediatr Blood Cancer. 2021 07; 68(7):e29026.

View in: PubMed
Ranganna K, Selvam C, Shivachar A, Yousefipour Z. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach. Int J Mol Sci. 2020 Nov 02; 21(21).

View in: PubMed
He B, Garmire L. Prediction of repurposed drugs for treating lung injury in COVID-19. F1000Res. 2020; 9:609.

View in: PubMed
Venugopal SV, Caggia S, Gambrell-Sanders D, Khan SA. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells. Prostate. 2020 04; 80(5):412-423.

View in: PubMed
Torres-Rever?n A, Rana M, Gorabi V, Rivera-Lopez LL, Appleyard CB. Short treatment with antalarmin alters adrenal gland receptors in the rat model of endometriosis. PLoS One. 2020; 15(1):e0227456.

View in: PubMed
Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol. 2020 10; 3(5):687-694.

View in: PubMed
Ezad S, Khan AA, Cheema H, Ashraf A, Ngo DTM, Sverdlov AL, Collins NJ. Ibrutinib-related atrial fibrillation: A single center Australian experience. Asia Pac J Clin Oncol. 2019 Oct; 15(5):e187-e190.

View in: PubMed

People

Explore

Similar Concepts

Top Journals